Viking therapeutics, inc. (VKTX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Mar'14
Cash flows from operating activities
Net loss

-30,542

-25,779

-23,569

-24,438

-23,436

-22,063

-20,908

-20,407

-18,907

-20,578

-20,137

-17,846

-16,366

-14,731

-16,178

-17,107

-21,279

-23,403

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Amortization of debt discount on notes payable

-

-

-

-

-

404

663

919

1,110

1,283

1,455

1,630

1,818

1,788

1,597

1,406

1,122

893

0

0

0

0

Amortization of investment premiums (accretion of investment discounts), net

-260

477

194

360

236

73

-128

-103

2

95

115

117

136

153

0

0

0

-

-

-

-

-

Amortization of financing costs

161

146

130

120

120

120

124

111

503

571

0

0

0

-

-

-

-

-

-

-

-

-

Amortization of non-cash clinical trial costs

-

140

265

329

575

666

887

1,071

1,177

994

0

0

0

-

-

-

-

-

-

-

-

-

Change in fair value of accrued license fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,381

0

0

0

-

Change in fair value of debt conversion feature liability

-

-

-

-

-

1,398

2,031

895

1,428

345

332

1,403

1,245

1,064

227

94

-864

-1,043

0

0

0

0

Stock-based compensation

4,361

3,743

3,384

3,323

3,032

2,608

2,354

1,949

1,659

1,451

1,446

1,422

1,571

1,794

1,963

2,243

3,225

2,601

0

0

0

0

Amortization of right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense related to operating lease liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized (gain) loss on investments

-8

-4

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

6,886

7,380

-976

-724

-254

137

1,625

953

40

-497

-480

-343

-306

-273

-516

504

876

1,079

0

0

0

0

Accounts payable

1,406

1,472

954

405

1,040

-508

-301

204

-1,091

264

608

331

750

677

382

577

631

219

0

0

0

0

Accrued expenses

4,402

2,394

2,212

1,944

1,728

1,468

654

-43

110

1,010

1,768

1,703

1,083

-141

-107

692

744

1,560

0

0

0

0

Lease liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-25,902

-24,752

-15,688

-17,793

-16,604

-18,755

-20,023

-17,849

-16,781

-14,758

-13,275

-12,601

-11,626

-11,071

-11,905

-12,651

-11,045

-8,731

0

0

0

0

Purchases of investments

319,623

362,406

463,272

417,381

415,143

348,204

176,710

125,807

48,748

22,526

17,764

17,101

22,829

16,922

0

0

0

-

-

-

-

-

Proceeds from maturities of investments

345,847

369,869

339,405

251,274

171,432

82,475

48,976

26,551

15,352

20,796

21,878

20,264

21,926

19,952

0

0

0

-

-

-

-

-

Net cash provided by (used in) investing activities

26,224

7,463

-123,867

-166,107

-243,711

-265,729

-127,734

-99,256

-33,396

-1,730

4,113

3,162

-903

3,029

0

0

0

-

-

-

-

-

Proceeds from issuances of common stock, net of underwriting discounts and commissions

-

-

-

-

-

296,607

311,127

147,172

78,634

22,352

0

0

0

-

-

-

-

-

-

-

-

-

Public offering and financing costs

-

-

-

-

-

765

858

704

630

500

195

548

1,054

1,096

1,073

1,362

2,821

2,782

0

0

0

-

Value of shares withheld related to employee tax withholding

194

151

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

595

887

1,001

168,413

238,302

300,275

314,695

148,321

82,174

22,400

8,675

7,672

12,929

10,348

9,281

8,468

22,174

22,214

0

0

0

0

Net increase (decrease) in cash and cash equivalents

917

-16,402

-138,554

-15,487

-22,013

15,791

166,938

31,216

31,997

5,912

-487

-1,766

399

2,306

914

-4,337

3,631

12

0

0

0

0

Supplemental disclosure of non-cash investing and financing transactions
Shares issued

-

-

-

-

-

-

-

-

-

1,800

0

0

0

-

-

-

-

-

-

-

-

-

Unpaid deferred public offering and other financing costs

0

-

-

-

-

-

203

301

260

140

0

0

0

-

0

0

0

-

-

-

-

-

Repurchases of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Deferred IPO costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0